Notice of Proposed Sale · 144
Liquidia Corporation
LQDANASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- LIQUIDIA CORPORATION
- Issuer CIK
- 0001819576
- SEC file number
- 001-39724
- Phone
- 9193284400
- Person for whose account securities are to be sold
- JASON ADAIR
- Relationships to issuer
- Officer
- Street
- 419 Davis Drive, Suite 100,
- City
- Morrisville
- State / country code
- NC
- Postal code
- 27560
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 73,631 | 5,231,482.55 | 89,508,891 | 08/21/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/21/2026 | Exercise of Stock Options | Issuer | 31,799 | N | 08/21/2026 | Cash |
| Common | 04/11/2024 | Restricted Stock Units | Issuer | 41,832 | N | 04/11/2024 | N/A |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| JASON ADAIR | Common | 07/13/2026 | 7,863 | 562,288.70 |
Seller — prior-sale row 1, entry 1
- Name
- JASON ADAIR
- Street
- 419 Davis Drive, Suite 100,
- City
- Morrisville
- State / country code
- NC
- Postal code
- 27560
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
The securities to be sold were acquired upon the vesting of restricted stock units during the period of 4/11/2024 through 4/11/2026
Notice signature
- Notice date
- 08/21/2026
- Signed
- /s/ JASON ADAIR
- Plan adoption dates
- 05/22/2026
Company context
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug approved in 2025 for the treatment of PAH. YUTREPIA is currently under development for other indications, including SSc-RP and PH-COPD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. To learn more about Liquidia, please visit www.liquidia.com.